The 18-month extension of the GATHER2 trial indicated continued benefit for patients receiving avacincaptad pegol, with efficacy gains increasing over time.
Arshad M. Khanani, MD, MA, FASRS
Advertisement
Articles by Arshad M. Khanani, MD, MA, FASRS
Advancements in drug durability and patient care are closing treatment gaps.
Advertisement
Latest Updated Articles
Shaping the future of retinal therapyPublished: February 19th 2025 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
4
AAO 2025: Diana Do, MD, reviews the real-world use of aflibercept 8 mg
5
.png "Optometry Times"){kind=logo}
